The Wistar Institute’s Paul M. Lieberman, Ph.D. and lab identified and tested a new method for targeting certain cancers caused by Epstein-Barr Virus (EBV), in the paper, “USP7 inhibitors destabilize EBNA1 and suppress EBV tumorigenesis,” from the Journal of Medical Virology.
Leave A Comment